高级检索
当前位置: 首页 > 详情页

Angiogenesis: a new surrogate histopathological marker is capable of differentiating between mild and significant portal hypertension

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China [2]Capital Med Univ, Int Sch, Beijing 100050, Peoples R China [3]China Japan Friendship Hosp, Dept Pathol, Beijing, Peoples R China
出处:
ISSN:

关键词: Cirrhosis Fibrosis area Microvessel density Nodule size Portal hypertension

摘要:
Aim: Angiogenesis is considered an important pathophysiological feature of portal hypertension. We investigated the ability of angiogenesis, as CD34-positive microvessel density (MVD), to differentiate portal pressure in a CCl4-induced rat cirrhosis model. Methods: Cirrhosis was induced by intraperitoneal injection of carbon tetrachloride in 46 male adult Sprague-Dawley rats. A catheter connected to a highly sensitive pressure transducer was inserted into the portal vein to continuously record portal pressure. Fibrosis area, nodule size and MVD were assessed by image morphometry. Results: Of 42 rats in which portal pressure was measured successfully, 27 (64%) had portal pressure >= 10 mmHg, defined as significant portal hypertension. MVD was 4.5-fold higher and fibrosis area 13.0-fold higher in rats with significant portal hypertension than in rats with portal pressure <10 mmHg. Portal pressure was significantly correlated with MVD (r=0.491, p<0.001) and fibrosis area (r=0.545, p<0.001) in all animals, but only MVD correlated with portal pressure (r=0.731 p<0.001) in rats with significant portal hypertension. The area under receiver operating characteristic curve for MVD in all rats was 0.953 (95% CI: 0.875-1.031) and optimum cutoff for MVD was 18/mm(2), with 96.3% sensitivity and 93.3% specificity. Conclusions: We found that MVD, measured by CD34 immunostaining, was better able than the fibrosis area to discriminate significant portal hypertension in rats, suggesting that MVD could be a surrogate marker for portal hypertension in patients with liver diseases.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 生物
小类 | 3 区 病理学 4 区 细胞生物学
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 细胞生物学 4 区 病理学
JCR分区:
出版当年[2013]版:
Q2 PATHOLOGY Q3 CELL BIOLOGY
最新[2023]版:
Q2 PATHOLOGY Q3 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2013版] 出版当年五年平均[2009-2013] 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者单位: [1]Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China [*1]Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, 95 Yong An Rd, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)